#+TITLE: Disorders of Branched Chain Amino Acid Catabolism
#+AUTHOR: Matthew Henderson, PhD, FCACB
#+DATE: \today

:PROPERTIES:
#+DRAWERS: PROPERTIES
#+LaTeX_CLASS: beamer
#+LaTeX_CLASS_OPTIONS: [presentation, smaller]
#+BEAMER_THEME: Hannover
#+BEAMER_COLOR_THEME: whale
#+BEAMER_FRAME_LEVEL: 2
#+COLUMNS: %40ITEM %10BEAMER_env(Env) %9BEAMER_envargs(Env Args) %4BEAMER_col(Col) %10BEAMER_extra(Extra)
#+OPTIONS: H:2 toc:nil
#+PROPERTY: header-args:R :session *R*
#+PROPERTY: header-args :cache no
#+PROPERTY: header-args :tangle yes
#+STARTUP: beamer
#+STARTUP: overview
#+STARTUP: hidestars
#+STARTUP: indent
#+BEAMER_HEADER: \subtitle{Part 1: Maple Syrup Urine Disease}
#+BEAMER_HEADER: \institute[NSO]{Newborn Screening Ontario | The University of Ottawa}
#+BEAMER_HEADER: \titlegraphic{\includegraphics[height=1cm,keepaspectratio]{../logos/NSO_logo.pdf}\includegraphics[height=1cm,keepaspectratio]{../logos/cheo-logo.png} \includegraphics[height=1cm,keepaspectratio]{../logos/UOlogoBW.eps}}
#+latex_header: \hypersetup{colorlinks,linkcolor=white,urlcolor=blue}
#+LaTeX_header: \usepackage{textpos}
#+LaTeX_header: \usepackage{textgreek}
#+LaTeX_header: \usepackage[version=4]{mhchem}
#+LaTeX_header: \usepackage{chemfig}
#+LaTeX_header: \usepackage{siunitx}
#+LaTeX_header: \usepackage{gensymb}
#+LaTex_HEADER: \usepackage[usenames,dvipsnames]{xcolor}
#+LaTeX_HEADER: \usepackage[T1]{fontenc}
#+LaTeX_HEADER: \usepackage{lmodern}
#+LaTeX_HEADER: \usepackage{verbatim}
#+LaTeX_HEADER: \usepackage{tikz}
#+LaTeX_HEADER: \usetikzlibrary{shapes.geometric,arrows,decorations.pathmorphing,backgrounds,positioning,fit,petri}
:END:
#+BEGIN_LaTeX
%\logo{\includegraphics[width=1cm,height=1cm,keepaspectratio]{../logos/NSO_logo_small.pdf}~%
%    \includegraphics[width=1cm,height=1cm,keepaspectratio]{../logos/UOlogoBW.eps}%
%}

\vspace{220pt}
\beamertemplatenavigationsymbolsempty
\setbeamertemplate{caption}[numbered]
\setbeamerfont{caption}{size=\tiny}
% \addtobeamertemplate{frametitle}{}{%
% \begin{textblock*}{100mm}(.85\textwidth,-1cm)
% \includegraphics[height=1cm,width=2cm]{cat}
% \end{textblock*}}

\tikzstyle{chemical} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=black, fill=none]
\tikzstyle{hardware} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=black, fill=gray!30]
\tikzstyle{ms} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=orange, fill=none]
\tikzstyle{msw} = [rectangle, rounded corners, text width=7em, minimum height=1em,text centered, draw=orange, fill=none]
\tikzstyle{label} = [rectangle,text width=8em, minimum height=1em, text centered, draw=none, fill=none]
\tikzstyle{hl} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=black, fill=red!30]
\tikzstyle{box} = [rectangle, rounded corners, text width=5em, minimum height=5em,text centered, draw=black, fill=none]
\tikzstyle{arrow} = [thick,->,>=stealth]
\tikzstyle{hl-arrow} = [ultra thick,->,>=stealth,draw=red]

#+END_LaTeX

* Introduction
** BCAAs

#+BEGIN_LaTeX
\centering
\chemname{\chemfig[][scale=.75]{^{+}H_3N-C(-[2]COO^{-})(-[6]CH(-[7]CH_3)(-[5]CH_3))-H}}{\small valine}
\chemname{\chemfig[][scale=.75]{^{+}H_3N-C(-[2]COO^{-})(-[6]CH_2-[6]CH(-[7]CH_3)(-[5]CH_3))-H}}{\small leucine}
\chemname{\chemfig[][scale=.75]{^{+}H_3N-C(-[2]COO^{-})(-[6]CH(-CH_3)-[6]CH_2-[6]CH_3)-H}}{\small isoleucine}

#+END_LaTeX

** BCAA Catabolism
\centering
#+ATTR_LATEX: :height 0.85\textheight
[[./figures/bcaa.png]]


* Biochemistry
** Maple Syrup Urine Disease
- Only BCAA disorder detected by plasma amino acids.
  - \Uparrow \Uparrow Leucine, also isoleucine and valine
    - Presence of Allo-isoleucine is pathognomonic
- - \Uparrow \alpha{}-ketoisocaproate, \alpha{}-keto-\beta{}-methylvaleric and \alpha{}-ketoisovaleric
** L-Alloisoleucine
- L-alloisoleucine is a branched chain amino acid and is a
  stereo-isomer of L-isoleucine.
- It is a common constituent of human plasma at low levels.
- Produced as a byproduct of isoleucine transamination.
- L-alloisoleucine differs from L-isoleucine by having having
  different stereochemistry around its beta carbon.

#+BEGIN_LaTeX
\centering
\chemname{\chemfig[][scale=.75]{H_{3}C-[1]-[7](<[6]CH_3)-[1](<:[2]NH_2)-[7](=[6]0)-[1]OH}}{\small L-isoleucine}
\chemname{\chemfig[][scale=.75]{H_{3}C-[1]-[7](<:[6]CH_3)-[1](<:[2]NH_2)-[7](=[6]0)-[1]OH}}{\small L-alloisoleucine}

#+END_LaTeX

** Rules 

[[./figures/aa_rules.png]]


VICKERY, H. B. (1947). Rules for the nomenclature of the natural amino
acids and related substances. The Journal of Biological Chemistry,
169(2), 237–245.
** BCAA Catabolism
- First two steps are shared
- *BCAT*: reversible transammination
  - BCAAs escape first pass hepatic metabolism
    - \downarrow expression of BCAT in the liver
  - Metabolized in skeletal muscle and adipose tissue
- *BCKDC*: irreversible oxidative decarboxylation and thioesterification
  - CoA derivatives are committed to oxidative phosphorylation
  - BCKDC is the regulated step in BCAA metabolism
    - product inhibition
    - phosporylation
    - transcription
** BCAT and BCKDC Reaction

\centering
#+ATTR_LATEX: :height 0.90\textheight
[[./figures/BCKD_Reaction.png]]

** Branched Chain \alpha{}-Ketoacid-Dehdrogenase Metabolic Machine
- 4-megadalton metabolic machine on the IMM organized around a 24-meric
  transacylase (E2b) cubic core
- E2b contains 24 identical subunits made up of three folded domains:
  - lipoyl (LD),
  - E1b/E3-binding (BD)
  - E2b core domains
- multiple copies of the following are attached to E2b via ionic interactions
  - decarboxylase (E1b),
  - dehydrogenase (E3),
  - specific kinase
  - specific phosphatase 

** Regulation of the BCKD Metabolic Machine
*** Feedback Inhibition
- product inhibition by branched chain acyl-CoAs
- \uparrow NADH:NAD^{+} ratio
*** Phosphorylation
- Inhibited by phosphorylation of E1\alpha Ser 293 
- \uparrow protein diet, adrenaline and glucogon dephosphorylate BCKD
- Phenylbutyrate prevents dephosphorylation 
*** Gene Expression
- subunit expression differentially regulated 

** Structure of the BCKD Metabolic Machine

\centering
#+ATTR_LATEX: :height 0.90\textheight
[[./figures/bckdmm.jpg]]

*** COMMENT Note 
The macromolecular structure (4 x 106 daltons in size) is organized
about a cubic transacylase (E2b) core, to which a decarboxylase (E1b),
a dehydrogenase (E3) are attached through ionic interactions. E2b of
the BCKD complex contains 24 identical subunits with each polypeptide
made up of three folded domains: lipoyl (LD), E1b/E3-binding (BD), and
the E2b core domains that are linked by flexible regions.

E1 alpah2bbeta2 heterotetramers or E3 homodimers are
attached to BD. The BCKD kinase and BCKD phosphatase that are not
shown bind to LD. E1b catalyzes the ThDP-mediated oxidative
decarboxylation of branched-chain alpha-ketoacids. The
ThDP-hydroxyacylidene moiety is transferred to a reduced lipoyl
prosthetic group (in the box) on LD. The flexible LD carries
S-acyldihydrolipoamide to the active site in the E2 core to generate
acyl-CoA. The reduced lipoyl moiety on LD is oxidized by E3 on BD with
the concomitant reduction of NAD+. The sum of the above component
reactions is the oxidative decarboxylation of branched-chain
alpha-ketoacids (Reproduced from Ævarsson et al.,
Nat. Struct. Biol. 6: 785-792, 2000).

** Leucine

\centering
[[./figures/leu.png]]

*** COMMENT
- CNS
  - compete for transport with other large neutral amino acids
    - LAT1 low Km
  - glutamate/GABA/glutamine cycle
    - \/ glutaminergic neurotransmitters
    - /\ ketoisocaproate -> mito disfunction
    - /\ mTOR -> decreased food intake
- Skeletal muscle
  - mTOR -> increased protein synthesis
  - /\ anabolism
  - /\ insulin secretion




* Testing
** NBS



